Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.33 | N/A | -23.13% |
management commentary, guidance changes, and full analysis available with Pro.
| -23.13% |
Tone: Defensive
Management acknowledged the difficulties faced this quarter but emphasized their commitment to pipeline advancement. They did not provide specific guidance for the future.
We are focused on advancing our pipeline despite the current challenges.
Our team remains committed to delivering value to our stakeholders.
Nektar Therapeutics reported a loss that was worse than expected, which typically raises concerns among investors. However, the stock still saw a slight increase of 0.5%, possibly due to broader market trends or investor optimism about the company's future pipeline. The lack of guidance may leave investors uncertain about the company's direction in the coming quarters.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERIPRISE FINL INC
Apr 25, 2011